SlidesetViral Hepatitis and Liver Disease1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract LB #4 Global Perspectives of People Living with Hepatitis B on Long-Acting Antivirals: Survey Results - Yasmin IbrahimView Slideset
SlidesetHIVTuberculosisViral Hepatitis and Liver Disease1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract #9 LAPaL: Your Free Digital Compass in the Evolving Long-Acting Therapeutics Landscape - Lobna GaayebView Slideset
SlidesetHIV1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract #8 VH3810109 (N6LS) Efficacy and Safety in Adults Who Are Virologically Suppressed: The EMBRACE Study - Rulan GrieselView Slideset
SlidesetTuberculosis1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract LB #3 Clinical Development of Long-Acting Formulations for TB Treatment and Prevention: Insights from the Bedaquiline Long-Acting TMC207TBC1006 Phase 1 Trial – Vivan CoxView Slideset
SlidesetTuberculosis1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract #7 First in Human Dose Predictions Scaled from Preclinical Pharmacokinetics for LAI Rifabutin - Doaa Ahmed MohamedView Slideset
SlidesetNTDTuberculosis1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract #6 Development of Long-Acting Telacebec (Q203) for Treatment of M. tuberculosis, M. ulcerans and M. leprae - Martina KovarovaView Slideset
SlidesetHIV1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract LB #2 Twice-Yearly Lenacapavir PrEP in Cisgender Gay Men, Transgender Women and Men, and Gender-Diverse People (PURPOSE 2) - Meredith ClementView Slideset
SlidesetHIV1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract #5 Cabotegravir and Rilpivirine in Pregnancy: A Multi-Center Study Evaluating HIV Viral Suppression, Perinatal and Neonatal Outcomes - William ShortView Slideset
SlidesetHIV1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract #4 Facilitators and Barriers to Long-Acting Injectable Antiretroviral Therapy Uptake among Youth Living with HIV in Cape Town, South Africa: A COM-B Analysis - Sheree SchwartzView Slideset
SlidesetHIV1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract #3 Novel Ultra-Long-Acting Injectable Formulations of Bictegravir - Xiaohong QiView Slideset
SlidesetHIV1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract #2 Utilization and Effectiveness of Cabotegravir + Rilpivirine in People with HIV (PWH) with Viremia at Treatment Initiation - Richard A. ElionView Slideset
SlidesetHIV1st International Workshop On Long Acting Anti-Infectives (LAAI) 2025Abstract LB #1 What Do Early Adopters of Long-Acting Injectable Cabotegravir-Rilpivirine Think About It? - Katerina ChristopoulosView Slideset
